The Centers for Medicare & Medicaid Services (CMS) has announced that its temporary program to cover GLP-1 drugs for obesity in Medicare, called the BALANCE model, will not launch as scheduled on Jan
Fielding, et al., l-Carnitine Supplementation in Recovery after Exercise, Nutrients, Mars 2018, 10(3): 349
114 In a controlled study enrolling 20 participants who received the VLCKD, a significant improvement in biochemical parameters was observed after 8 weeks of KD adherence, which included a reduction in BMI, LDL-C, TGs, insulinemia, and liver transaminases
[4] [6] This relationship is bidirectional and complex, involving: Inflammatory pathways that affect both metabolic and mental health Hormonal dysregulation impacting mood and stress responses Psychosocial factors including stigma, body image concerns, and chronic disease burden Lifestyle factors such as reduced physical activity and poor sleep quality When GLP-1 medications improve glycaemic control, facilitate weight loss, and enhance overall metabolic health, patients may experience secondary improvements in psychological wellbeing